Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Antibody
416€ (200 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx432301
tested applications
P-ELISA, WB
Description
AKR1B10 Antibody is a Goat Polyclonal antibody against AKR1B10.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) |
| Host | Goat |
| Reactivity | Human |
| Recommended Dilution | P-ELISA: 1/8000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Size 1 | 200 µl |
| Form | Liquid |
| Tested Applications | P-ELISA, WB |
| Buffer | Tris saline, pH 7.3, containing 0.02% sodium azide and 0.5% bovine serum albumin. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Gene ID | 57016 |
| NCBI Accession | NP_064695.2 |
| Alias | AKR1B10,AKR1B11,AKR1B12,ALDRLn,ARL-1,ARL1 |
| Background | Antibody anti-AKR1B10 |
| Status | RUO |
| Note | Concentration: 0.5 mg/ml - |
Descripción
AKR1B10 is primarily expressed in the liver, intestines, and lungs, where it catalyzes the reduction of carbonyl compounds, including aldehydes derived from lipid peroxidation and retinoic acid metabolism. AKR1B10 plays a pivotal role in detoxifying reactive aldehydes, thereby protecting cells from oxidative stress and lipid damage. It also regulates cellular retinoic acid levels, influencing cell proliferation, differentiation, and apoptosis. Overexpression of AKR1B10 is strongly associated with various cancers, particularly hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), and colorectal cancer, where it enhances tumor progression, chemoresistance, and metastasis. AKR1B10 contributes to drug resistance by metabolizing chemotherapeutic agents and supporting lipid synthesis for tumor growth. Its role in fatty acid biosynthesis links it to metabolic reprogramming in cancer cells, promoting proliferation and survival. AKR1B10 is considered a promising biomarker for cancer diagnosis and prognosis, as well as a therapeutic target for improving cancer treatment outcomes.
Related Products
Human AKR1B10(Aldo-keto reductase family 1 member B10) ELISA Kit
Ver Producto
Recombinant Human akr1b10
Ver Producto